Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by an educational grant from Insmed.
Patient, Provider, & Caregiver Connection™: Patient Perspectives in Non-Tuberculous Mycobacteria Lung Disease
Release Date: August 31, 2021
Expiration Date: August 31, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Insmed.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This online educational activity is directed toward pulmonologists, NPs and PAs, and additional members of the multidisciplinary care team who treat patients with bronchiectasis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the diagnostic approach to nontuberculous mycobacterial lung disease (NTM-LD)
- Evaluate the efficacy and safety profiles of antibiotics used in the treatment of NTM-LD
- Develop management plans for patients presenting with NTM-LD based on shared goals of therapy
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Chair
Professor of Public Health, Infectious Diseases, Ophthalmology
Oregon Health & Science University
Portland, OR
Disclosures: Grant/Research Support: Insmed; Consultant: Insmed, Paratek Pharmaceuticals, Red Hill Biopharma, Spero Therapeutics.
Faculty
Professor of Medicine
Division of Mycobacterial and Infectious Diseases
Department of Medicine
National Jewish Health
Denver, CO
Disclosures: Grant Research Support: Amgen, Pfizer, Takeda Pharmaceutical, Adaptive Biotechnologies, Novartis Pharmaceuticals, Spectrum Pharmaceuticals, AbbVie, Bristol Myers Squibb.
Douglas Bitter
Patient
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.